StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

Gilead Sciences consolidated revenues — United States ($M) ($M)

Form 10-Q / 10-K Disaggregated Revenue & Geographic Information

Latest, FY2025
20,876
Period ended Dec 31, 2025
Change on a year earlier
+1.4%
20,591 in FY2024
History
12 years
Since FY2014
Sources
9
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedConsolidated revenues — United States ($M) ($M)Year on yearSource
FY2025Dec 31, 202520,876+1.4%Form 10-K (filed 2026-02-24) ↗
FY2024Dec 31, 202420,591+5.9%Form 10-K (filed 2026-02-24) ↗
FY2023Dec 31, 202319,438+2.9%Form 10-K (filed 2026-02-24) ↗
FY2022Dec 31, 202218,884-2.0%Form 10-K (filed 2025-02-28) ↗
FY2021Dec 31, 202119,267+5.8%Form 10-K (filed 2024-02-23) ↗
FY2020Dec 31, 202018,217+9.4%Form 10-K (filed 2023-02-22) ↗
FY2019Dec 31, 201916,645+2.3%Form 10-K (filed 2022-02-23) ↗
FY2018Dec 31, 201816,269-10.6%Form 10-K (filed 2021-02-25) ↗
FY2017Dec 31, 201718,194-6.0%Form 10-K (filed 2019-02-26) ↗
FY2016Dec 31, 201619,354-8.9%Form 10-K (filed 2019-02-26) ↗
FY2015Dec 31, 201521,234+16.8%Form 10-K (filed 2018-02-27) ↗
FY2014Dec 31, 201418,182–Form 10-K (filed 2017-02-27) ↗

Breakdown

What makes up consolidated revenues — united states ($m)

Cite this data

StockData. (2026). Gilead Sciences Consolidated revenues — United States ($M) ($M), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/geo_rev_us

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.